CSLCSLLY +0.70%73 5-Year Yield-on-Cost % is 5.75 as of Jun. 29, 2026, which is 225% above its 10-year median of 1.77. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $48.70 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 153 Biotechnology companies, CSL ranks better than 80.39% on this metric.
CSL's yield on cost for the quarter that ended in Dec. 2025 was 5.75.
The historical rank and industry rank for CSL's 5-Year Yield-on-Cost % or its related term are showing as below:
CSLLY'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.21 Med: 1.77 Max: 7.12
Current: 5.75
During the past 13 years, CSL's highest Yield on Cost was 7.12. The lowest was 1.21. And the median was 1.77.
CSLLY's 5-Year Yield-on-Cost % is ranked better than 80.39% of 153
companies
in the Biotechnology industry
Industry Median: 1.77
vs CSLLY: 5.75
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
CSL 5-Year Yield-on-Cost % Related Terms
CSLLY vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, CSL's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where CSL's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
CSL (CSLLY) has a 5-Year Yield-on-Cost % of 5.75 as of Jun. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CSL and its competitors. This is 225% above median its historical median of 1.77. Over the past decade, CSL's 5-Year Yield-on-Cost % has ranged from 1.21 to 7.12. According to the industry distribution chart, CSL ranks #30 out of 153 companies in the Biotechnology industry, placing it in the top 19.6%.
Is CSL's 5-Year Yield-on-Cost % too high?
CSL's current 5-Year Yield-on-Cost % of 5.75 is 225% above median its 10-year median of 1.77. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 7.12. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.77. CSL's value of 5.75 is 224.9% above this industry median. Based on the distribution chart, CSL ranks #30 out of 153 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #30 out of 153 companies for 5-Year Yield-on-Cost %. This places CSL in the top 20% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 1.77. CSL's value of 5.75 is 224.9% above this benchmark. Historically, CSL's own 5-Year Yield-on-Cost % has ranged from 1.21 to 7.12 over the past decade. While the company's 10-year median is 1.77 vs. the industry median of 1.77, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.77, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current 5-Year Yield-on-Cost % of 5.75 is 224.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CSL and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current 5-Year Yield-on-Cost % is 5.75, which is 225% above median its own 10-year median of 1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.70, compared to a current price of $20.12 — trading 58.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.75, which is 225% above median its 10-year median of 1.77 and 224.9% above the Biotechnology industry median of 1.77. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For CSL (CSLLY), the current 5-Year Yield-on-Cost % is 5.75 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $20.12 is trading 58.7% below its estimated GF Value™ of $48.70.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
5-Year Yield-on-Cost %: 5.75 (225% above median its 10-year median of 1.77)
GF Value™: $48.70 vs. price of $20.12 (58.7% below fair value)
Industry Position: 224.9% above the Biotechnology median (#30 of 153)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 